semaglutide po New research from Dr. Hien Ear at the University of Iowa is raising a potential risk of semaglutide, a widely used medication for type 2 diabetes and obesity, for people with # New in the August 14,

Diabetes care 2021;44:S111-S124 Dennis JM

[ref] A study in rats found that the therapeutic effect of BPC-157 was achieved through consolidating the stimulating and inhibiting effects of the NO system

I highly recommend it to anyone interested in understanding how these medications fit into a comprehensive approach to health and longevity.Jordan D Metzl, MD, Sports Medicine Physician, Hospital for Special Surgery and Author of Push As use of GLP1 medications grows, it is essential to understand how to best support bone health, preserve muscle mass, and optimize longterm function and wellbeing

In a landmark study called the STEP program, which included over 4500 adults with overweight or obesity, glp-1 was found to lead to significant weight loss compared to a placebo

14,64,65 Drug-induced AP and other risk factors, such as smoking, are receiving increasing attention